Reboxetine (REB) is a member of a new class of antidepressant drugs, which selectively inhibit the neuronal reuptake of noradrenaline. It is devoid of any affinity for neurotransmitter receptors nor does it inhibit monoamine oxidases A or B. Since our earlier studies have shown that antidepressant drugs administered repeatedly increase the responsiveness of alpha1-adrenergic receptors and induc...

Background. The prevalence of major depression in stage 5 chronic kidney disease (CKD) varies between 14 and 30%. Patients with CKD who are depressed have a worse quality of life, are hospitalized more often and die sooner than those who are not depressed. Antidepressant drugs are effective in the general population, but whether they improve outcomes in CKD is uncertain. Drug pharmacokinetics a...

Amaç: Antidepresanlar reseptör özelliklerine göre kardiak otonomik sinir sistemi işleyişi üzerine farklı etkiler gösterebilir. Bu nedenle farklı gruplardaki antidepresanların değişen boyutlarda kardiak değerleri etkilemesi beklenebilir. Bu çalışma bir serotonin ve noradrenalin geri alım inhibitörü olan venlafaksin ile bir seçici noradrenalin geri alım inhibitörü olan reboksetinin elektrokardiyo...